LOS ANGELES CAPITAL MANAGEMENT LLC

Position in RGNX — REGENXBIO Inc.

CIK 1177206 LOS ANGELES, CA

Position in RGNX

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$2,611

-$114,365 QoQ

Shares Held

218

-98.4% QoQ

Ownership

0.000%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#148

of 163 holders

Holding Since

Mar 2022

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names. RGNX ranks #159 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	729,635	$219,642,024
2	HALO	Halozyme Therapeutics, Inc.	1,938,035	$151,689,999
3	CAI	Caris Life Sciences, Inc.	3,958,531	$70,541,022
4	INCY	Incyte Corp	578,986	$65,633,852
5	VRTX	Vertex Pharmaceuticals Inc / Ma	130,802	$64,973,277
6	EXEL	Exelixis, Inc.	1,159,457	$63,086,055
7	REGN	Regeneron Pharmaceuticals, Inc.	98,585	$61,471,690
8	RPRX	Royalty Pharma plc	877,674	$49,211,181

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,611	218	-98.4%	Shares	Sole	2026-08-13
2026-03-31	$116,976	13,959	-59.0%	Shares	Sole	2026-05-08
2025-12-31	$490,377	34,054	-63.2%	Shares	Sole	2026-02-11
2025-09-30	$893,802	92,622	-26.1%	Shares	Sole	2025-10-20
2025-06-30	$1,029,599	125,408	+543.8%	Shares	Sole	2025-08-07
2023-03-31	$368,347	19,479	-43.1%	Shares	Sole	2023-05-04
2022-12-31	$777,016	34,260	-7.2%	Shares	Sole	2023-02-06
2022-09-30	$976,271	36,938	-39.4%	Shares	Sole	2022-11-02
2022-06-30	$1,504,724	60,920	+115.7%	Shares	Sole	2022-08-05
2022-03-31	$937,285	28,240	—	Shares	Sole	2022-05-06
No filing history on record for this holder in this stock.